Showing results (1-10 of 120) with videos related to
Sort By:
Pageof 12
Current Opinion in Pediatrics|May 14, 2005
Novel, mechanism-based therapies for cystic fibrosisRonald C RubensteinMolecular Diagnosis & Therapy|October 7, 2006
Targeted therapy for cystic fibrosis: cystic fibrosis transmembrane conductance regulator mutation-specific pharmacologic strategiesRonald C RubensteinAmerican Journal of Mental Deficiency|July 1, 1976
Release from proactive interference in short-term memory in mentally retarded personsD B Reutener, C RubensteinAmerican Journal of Respiratory and Critical Care Medicine|February 26, 1998
A pilot clinical trial of oral sodium 4-phenylbutyrate (Buphenyl) in deltaF508-homozygous cystic fibrosis patients: partial restoration of nasal epithelial CFTR functionR C Rubenstein, P L ZeitlinHeart Failure Reviews|March 23, 2011
Atrioventricular junction ablation and pacemaker implantation for heart failure associated with atrial fibrillation: potential issues and therapies in the setting of acute heart failure syndromeJason C Rubenstein, James A RothFrontiers in Pediatrics|January 31, 2014
On preventing the extinction of the physician-scientist in pediatric pulmonologyRonald C Rubenstein, James L KreindlerAmerican Journal of Physiology. Cell Physiology|February 9, 2000
Sodium 4-phenylbutyrate downregulates Hsc70: implications for intracellular trafficking of DeltaF508-CFTRR C Rubenstein, P L ZeitlinAmerican Journal of Physiology. Lung Cellular and Molecular Physiology|June 19, 2001
Sodium 4-phenylbutyrate downregulates HSC70 expression by facilitating mRNA degradationR C Rubenstein, B M LyonsFrontiers in Pharmacology|July 24, 2012
Molecular Chaperones as Targets to Circumvent the CFTR Defect in Cystic FibrosisRebecca A Chanoux, Ronald C RubensteinPageof 12